Enzyvant Logo White Verticle

Patient Focused. Results Driven.



Transformative therapies for rare diseases with high unmet needs.


Innovative partnerships that create new opportunities in the rare disease field.


On our commitment to the patients, families, and communities we serve.


Enzyvant Pipeline Graphic


Complete DiGeorge Anomaly

Children with complete DiGeorge Anomaly are born without a thymus gland, resulting in primary immunodeficiency. The disease is almost uniformly fatal within the first 24 months of life if untreated.


Farber Disease

Farber disease is an ultra-rare lysosomal storage disease caused by a mutation in both alleles of the ASAH1 gene, resulting in the deficiency of the lysosomal enzyme acid ceramidase.

July 9, 2018

Enzyvant, announced today that it has initiated its rolling submission of a Biologics License Application (BLA) for RVT-802 to the U.S. Food and Drug Administration (FDA).

July 5, 2018

Enzyvant today announced that it has formed a partnership with Visikol, a contract research organization focused on digital pathology and drug discovery.

February 28, 2018

Re:GenerationHope raises awareness and funds for the complete DiGeorge Anomaly

Contact us for more information.